Concizumab-mtci Drug Asset Due Diligence Report 2026

This Concizumab-mtci Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Concizumab-mtci can convert its Monoclonal antibody profile and TFPI biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Concizumab-mtci (query alias: concizumab)
Modality / target	Monoclonal antibody; TFPI; TFPI inhibitors
Highest global status	Approved
Originator	Novo Nordisk A/S
Active developers	Novo Nordisk A/S, Novo Nordisk Pharmaceuticals Pty Ltd., Novo Nordisk Canada, Inc.

The MCP disease footprint includes Hemophilia, Hemophilia A, Hemophilia B. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05135559	Phase 3	Active, not recruiting	153	For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
NCT06831734	Not Applicable	Enrolling by invitation	30	Number of adverse reaction (AR)
NCT06285071	Not Applicable	Enrolling by invitation	23	Number of adverse reaction (AR)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Concizumab efficacy in patients with Hemophilia A/B without inhibitors from the Phase 3 explorer8 study: A post-hoc sensitivity analysis for the intra-patient comparison of concizumab with previous prophylaxis

Phase 3; n=51; evaluation: Positive. Reported fields: ABR = 2.2 Unit ( 0.8 - 6.2); ABR = 2.8 Unit ( 1.76 - 4.57)

FDA-Approved Drugs-ALHEMO-CLINICAL STUDIES(II)

Phase 3; n=156; evaluation: Positive. Reported fields: ABR(hemophilia A) = 19.3 Event/year (95%CI, 11.25 - 33.03); ABR(hemophilia A) = 2.7 Event/year (95%CI, 1.63 - 4.59)

Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Phase 3; n=134; evaluation: not stated. Reported fields: Rate of Treated Spontaneous and Traumatic Bleeding Episodes(Median): Annualised bleeding rate ratio = 0.14(95% CI, 0.07 - 0.29), P-Value = <0.001; Rate of Treated Spontaneous and Traumatic Bleeding Episodes(Median): Annualised bleeding rate ratio = 0.14(95% CI, 0.07 - 0.29), P-Value = <0.001; Rate of Treated Spontaneous and Traumatic Bleeding Episodes(Median) = 0.0 Events per year (Inter-Quartile Range, 0.0 - 3.3)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Concizumab-mtci addresses Hemophilia, Hemophilia A, Hemophilia B. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: TFPI records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-17	Nanolek and Alphamab have entered into an agreement to launch a drug for the prevention of bleeding in hemophilia patients across Eurasian countries.	Phase 3	Financial terms not disclosed
2023-09-20	苏州康宁杰瑞与远大生命科学集团就TFPI单克隆抗体KN057达成合作	Phase 2	US$500.0M stated total
2010-11-19	Baxter Announces Acquisition of All Hemophilia-Related Assets of Archemix and an Exclusive License of Its Anti-TFPI Aptamer Technology	Phase 1	US$30.0M upfront; US$285.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Pharmaceutical formulation of concizumab and method of production thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO